Swedish Orphan Biovitrum

Tweet this page
<
2018
2019
2020
2021
2022
2023
2024
>
Registration as it was on 30 Oct 2024
How to read and use this data card.
Download this datacard
The following entries are flagged as duplicates of this organisation: 050036210658-03

Overview

Lobbying Costs

300,000€ - 399,999€

Financial year: Jan 2023 - Dec 2023

Lobbyists (Full time equivalent)

2 Fte (2)

Lobbyists with EP accreditation

1

High-level Commission meetings

0

Lobbying Costs over the years

  • Info

    Swedish Orphan Biovitrum   (Sobi)

    EU Transparency Register

    232923831740-31 First registered on 07 Jun 2018

    Goals / Remit

    Sobi is a international pharmaceutical company specialized in rare diseases developing and providing access to innovative treatments in the areas of haematology, immunology and specialty care.

    Sobi offers an integrated process, from in-house research and development in protein characterisation, biologics manufacturing and industrialisation, to commercialisation of products for rare diseases. Partnering with stakeholders and facilitating effective and timely rare-disease therapy development, including an extensive and robust distribution network, creates unique opportunities for us to add value to the rare-disease field.

    Main EU files targeted

    Rare disease policies (OMP & Paediatric regulation)
    General Pharmaceutical Legislation
    Pharmaceutical IP
    EU HTA
    Security of supply
    EMA Regulatory Strategy 2025

    Address

    Head Office
    Norra Stationsgatan 93A
    Stockholm SE-112 76
    SWEDEN
    EU Office
    Swedish Orphan Biovitrum (Belgium) BVHermeslaan 11
    Zaventem 1932
    BELGIUM

    Website

    https://www.sobi.com/en

  • People

    Total lobbyists declared

    2

    Employment timeLobbyists
    100%2

    Lobbyists (Full time equivalent)

    2

    Lobbyists with EP accreditation

    All Lobbyists with EP accreditation over time

    1 accreditations were / are live (in bold) for the selected state of 22 Dec 2024

    Name Start date End Date
    Mihaela Veringa 17 Sep 2024 17 Sep 2025
    Ms Mihaela VERINGA 26 May 2022 26 May 2023

    Complementary Information

    None declared

    Person in charge of EU relations

    Data not provided by Register Secretariat due to GDPR

    Person with legal responsibility

    Data not provided by Register Secretariat due to GDPR

  • Categories

    Category

    Companies & groups

  • Networking

    Affiliation

    Sobi is member of EUCOPE
    https://www.eucope.org/members/

    Member organisations

    None declared

  • Financial Data

    Interests represented

    Promotes their own interests or the collective interests of their members

    Closed financial year

    Jan 2023 - Dec 2023

    Lobbying costs for closed financial year

    300,000€ - 399,999€

    Major contributions in closed year

    None declared

    Intermediaries for closed year

    NameAmount
    european confederation of pharmaceutical entrepreneurs 25,000€ - 49,999€
    incisive health 50,000€ - 99,999€

    Intermediaries for current year

    Name
    incisive health
    eucope

    Closed year Costs

    300,000€ - 399,999€

    Other financial info

    None declared

  • EU Structures

    Groups (European Commission)

    None declared

    Groups (European Parliament)

    N/A

    Communication activities

    - European Commission Regulation on health technology assessment and amending Directive 2011/24/EU
    - European Commission study on the evaluation of the EU Orphan & Paediatric legislation
    - European Commission Pharmaceutical Strategy
    - European Parliament/EU Commission EU4Health Programme (particularly for rare diseases, ERNs)

    Other activities

    None declared

  • Meetings

    Meetings

    None declared

Download this datacard